Rheumatology Journals
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Rheumatology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
rheumatoid arthritis  rheumatoid arthritis
lupus  lupus
polymyalgia  polymyalgia
sjogrens  sjogrens
fibromyalgia  fibromyalgia
amyloidosis  amyloidosis
vasculitis  vasculitis
urate  urate
raynauds  raynauds
myositis  myositis
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Are bisphosphonates effective and safe in patients with low serum vitamin D levels?
Antoniucci DM et al. – Study concludes that physicians should continue to prescribe adequate supplies of vitamin D within the target of therapy; for example, above 50 nmol/l during therapy with bisphosphonates, since adequate vitamin D levels counteract elevated parathyroid hormone levels, reduce bone resorption and have a positive effect on neuromuscular performance and on the risk of falling and bone strength.

Methods
  • Aim was to investigate if vitamin D deficiency may blunt the increase in bone mineral density during treatment with bisphosphonates (etidronate)
  • Data was analyzed from 1000 randomly selected pts from alendronate Phase III Trials, FIT 1 and FIT 2
  • All pts were treated with alendronate
  • Pts who had a daily calcium intake of <1000 mg were supplied with 500 mg calcium and 250 IU cholecalciferol

Results
  • No difference in the change in BMD of the lumbar spine and hips pts with vit D deficiency, vit D insufficiency and sufficient vit D levels at baseline
  • At first sight, it seems reassuring that baseline vit D levels do not interfere with the treatment effect
[more...]
Sponsor

Read a Different Specialty

General Rheumatology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General Rheumatology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.